tiprankstipranks
Advertisement
Advertisement
Psychedelic: Compass Pathways, NRx Pharma report earnings results
PremiumThe FlyPsychedelic: Compass Pathways, NRx Pharma report earnings results
1M ago
GH Research Publishes Phase 2b GH001 TRD Data and Highlights Severity-Independent Efficacy
Premium
Company Announcements
GH Research Publishes Phase 2b GH001 TRD Data and Highlights Severity-Independent Efficacy
1M ago
GH Research announces publication of Phase 2b results for mebufotenin
Premium
The Fly
GH Research announces publication of Phase 2b results for mebufotenin
1M ago
GH Research: Advancing Phase 3 TRD Program Post‑Hold with Strong Cash Runway Supports Buy Rating
PremiumRatingsGH Research: Advancing Phase 3 TRD Program Post‑Hold with Strong Cash Runway Supports Buy Rating
2M ago
GH Research price target raised to $42 from $39 at Citizens
Premium
The Fly
GH Research price target raised to $42 from $39 at Citizens
2M ago
GH Research: Phase 3 Readiness, Expanding Indications, and Valuation Upside Reinforce Buy Rating
Premium
Ratings
GH Research: Phase 3 Readiness, Expanding Indications, and Valuation Upside Reinforce Buy Rating
2M ago
GH Research price target raised to $40 from $33 at RBC Capital
PremiumThe FlyGH Research price target raised to $40 from $33 at RBC Capital
3M ago
GH Research to Present at RBC Capital Markets Psychedelics Symposium
Premium
Company Announcements
GH Research to Present at RBC Capital Markets Psychedelics Symposium
3M ago
GH Research Showcases GH001 Depression Data at ACNP 2026 Mini‑Panel
Premium
Company Announcements
GH Research Showcases GH001 Depression Data at ACNP 2026 Mini‑Panel
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100